Aether Industries Limited

NSEI:AETHER Stock Report

Market Cap: ₹107.9b

Aether Industries Valuation

Is AETHER undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AETHER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AETHER's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AETHER's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AETHER?

Key metric: As AETHER is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AETHER. This is calculated by dividing AETHER's market cap by their current earnings.
What is AETHER's PE Ratio?
PE Ratio133.7x
Earnings₹807.30m
Market Cap₹107.93b

Price to Earnings Ratio vs Peers

How does AETHER's PE Ratio compare to its peers?

The above table shows the PE ratio for AETHER vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.3x
GLS Glenmark Life Sciences
31.3x23.4%₹132.5b
500126 Procter & Gamble Health
39x11.3%₹84.9b
532482 Granules India
26.3x22.1%₹128.3b
BLUEJET Blue Jet Healthcare
56.5x24.1%₹94.8b
AETHER Aether Industries
133.7x44.8%₹107.9b

Price-To-Earnings vs Peers: AETHER is expensive based on its Price-To-Earnings Ratio (133.7x) compared to the peer average (38.3x).

Price to Earnings Ratio vs Industry

How does AETHER's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$72.79m
524652 Ind-Swift
2xn/aUS$13.15m
No more companies available in this PE range
AETHER 133.7xIndustry Avg. 32.7xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AETHER is expensive based on its Price-To-Earnings Ratio (133.7x) compared to the Indian Pharmaceuticals industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is AETHER's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AETHER PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio133.7x
Fair PE Ratio56.1x

Price-To-Earnings vs Fair Ratio: AETHER is expensive based on its Price-To-Earnings Ratio (133.7x) compared to the estimated Fair Price-To-Earnings Ratio (56.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AETHER forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹814.20
₹1,097.00
+34.7%
2.9%₹1,135.00₹1,060.00n/a4
Nov ’25₹852.85
₹1,097.00
+28.6%
2.9%₹1,135.00₹1,060.00n/a4
Oct ’25₹949.05
₹1,047.50
+10.4%
4.6%₹1,117.00₹983.00n/a4
Sep ’25₹890.25
₹1,047.50
+17.7%
4.6%₹1,117.00₹983.00n/a4
Aug ’25₹895.95
₹1,047.00
+16.9%
4.6%₹1,115.00₹983.00n/a4
Jul ’25₹927.00
₹1,046.50
+12.9%
6.7%₹1,153.00₹968.00n/a4
Jun ’25₹804.00
₹1,046.50
+30.2%
6.7%₹1,153.00₹968.00n/a4
May ’25₹833.50
₹1,084.25
+30.1%
4.2%₹1,153.00₹1,029.00n/a4
Apr ’25₹798.45
₹1,083.25
+35.7%
3.7%₹1,124.00₹1,029.00n/a4
Mar ’25₹869.60
₹1,083.25
+24.6%
3.7%₹1,124.00₹1,029.00n/a4
Feb ’25₹866.05
₹1,068.00
+23.3%
3.7%₹1,120.00₹1,024.00n/a3
Jan ’25₹882.45
₹1,071.33
+21.4%
4.1%₹1,130.00₹1,024.00n/a3
Dec ’24₹794.85
₹1,071.33
+34.8%
4.1%₹1,130.00₹1,024.00n/a3
Nov ’24₹870.05
₹1,095.00
+25.9%
3.2%₹1,130.00₹1,060.00₹852.852
Oct ’24₹968.45
₹1,085.00
+12.0%
2.3%₹1,110.00₹1,060.00₹949.052
Sep ’24₹990.75
₹1,085.00
+9.5%
2.3%₹1,110.00₹1,060.00₹890.252
Aug ’24₹1,093.25
₹1,085.00
-0.8%
2.3%₹1,110.00₹1,060.00₹895.952
Jul ’24₹1,067.90
₹1,070.00
+0.2%
0.9%₹1,080.00₹1,060.00₹927.002
Feb ’24₹879.10
₹892.50
+1.5%
18.8%₹1,060.00₹725.00₹866.052
Jan ’24₹839.15
₹892.50
+6.4%
18.8%₹1,060.00₹725.00₹882.452
Dec ’23₹908.85
₹892.50
-1.8%
18.8%₹1,060.00₹725.00₹794.852

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

IOL Chemicals and Pharmaceuticals

₹20.5b

Manufactures and sells pharmaceutical and chemical products in India and internationally.

IOLCP

₹348.90

7D

-11.3%

1Y

-16.9%

Solara Active Pharma Sciences

₹35.8b

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

SOLARAPP

₹458.00

7D

-3.8%

1Y

n/a

Caplin Point Laboratories

₹150.9b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,988.75

7D

-1.2%

1Y

56.6%